Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Estrone sulfate
Drug ID BADD_D00835
Description Estrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, treatment of vaginal atrophy, treatment of some types of breast cancer (particularly in men and postmenopausal women), treatment of prostate cancer and prevention of osteoporosis.
Indications and Usage Estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis.
Marketing Status Discontinued
ATC Code G03CA07; G03CC04
DrugBank ID DB04574
KEGG ID D00312
MeSH ID C017296
PubChem ID 3001028
TTD Drug ID Not Available
NDC Product Code Not Available
Synonyms estrone sulfate | oestrone sulphate | estrone-3-sulfate | estrone sulfate, 16-(14)C-labeled | Evex | estrone sulfate, potassium salt | potassium estrone sulfate | estrone sulfate, sodium salt | sodium estrone sulfate | estrone sulfate, 14C-labeled | estrone sulfate, ammonium salt
Chemical Information
Molecular Formula C18H22O5S
CAS Registry Number 481-97-0
SMILES CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash generalised23.03.13.002--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Tenderness08.01.08.005--Not Available
Tension19.06.02.005--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombophlebitis superficial24.01.02.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.001--
Uterine haemorrhage24.07.03.004; 21.07.01.005--
Uterine leiomyoma16.04.02.001; 21.07.02.004--Not Available
Vaginal discharge21.08.02.002--
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vaginal inflammation21.14.02.001--
Venous thrombosis24.01.01.008--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003--Not Available
Weight increased13.15.01.006--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Endometrial thickening21.07.01.013--Not Available
Angiopathy24.03.02.007--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages